CPT® Code 38227

1. Indications

The indications for chimeric antigen receptor T-cell (CAR-T) therapy, as outlined in the provided data, include the treatment of specific types of cancers where traditional therapies may not be effective. This therapy is particularly indicated for patients with certain hematologic malignancies, such as:

• Acute Lymphoblastic Leukemia (ALL) - A type of cancer that affects the blood and bone marrow, characterized by the overproduction of immature lymphocytes.
• Diffuse Large B-Cell Lymphoma (DLBCL) - A fast-growing form of non-Hodgkin lymphoma that arises from B-cells, which are a type of white blood cell.
• Multiple Myeloma - A cancer of plasma cells, which are a type of white blood cell responsible for producing antibodies.

2. Procedure

The procedure for chimeric antigen receptor T-cell (CAR-T) therapy involves several critical steps that ensure the successful preparation and administration of the modified T-cells. Each step is essential for the overall effectiveness of the therapy.

• Step 1: Blood Collection - The initial step involves the withdrawal of blood from the patient, which may occur over one or more days. This process is crucial as it allows for the collection of T-lymphocytes, which are the target cells for genetic modification.
• Step 2: T-Lymphocyte Separation - Following blood collection, the T-lymphocytes are separated from the other components of the blood. This separation is typically performed using apheresis, a process that isolates specific blood cells for further processing.
• Step 3: Genetic Engineering - The separated T-lymphocytes are then taken to a laboratory or manufacturing facility where they undergo genetic engineering. An inactive virus is introduced into the T-cells, which carries the genetic instructions necessary for the production of chimeric antigen receptors (CARs) on the T-cell surface.
• Step 4: Expansion of CAR-T Cells - After the T-cells have been genetically modified to express CARs, they are cultured and expanded in the laboratory. This step is critical as it increases the number of CAR-T cells to hundreds of millions, ensuring that there are sufficient cells for effective treatment.
• Step 5: Lymphodepleting Chemotherapy - While the CAR-T cells are being manufactured, the patient receives lymphocytic cell-depleting chemotherapy. This treatment is designed to reduce the number of existing lymphocytes in the patient’s body, creating a more favorable environment for the infused CAR-T cells to thrive and function.
• Step 6: Infusion of CAR-T Cells - Once the CAR-T cells are ready and the patient has completed the preparatory chemotherapy, the final step is the infusion of the engineered CAR-T cells back into the patient. This infusion allows the CAR-T cells to circulate in the bloodstream and seek out cancer cells to destroy.

3. Post-Procedure

After the administration of chimeric antigen receptor T-cell (CAR-T) therapy, patients are monitored closely for any potential side effects and to assess the effectiveness of the treatment. Common post-procedure care includes managing symptoms related to the infusion, such as fever, chills, and fatigue. Patients may also experience cytokine release syndrome (CRS), a common reaction to CAR-T therapy that can cause flu-like symptoms. Ongoing follow-up appointments are essential to evaluate the patient's response to the therapy and to monitor for any signs of cancer recurrence. Additionally, healthcare providers may implement supportive care measures to help manage any adverse effects and ensure the patient's overall well-being during the recovery phase.